Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311
Debt
Debt-to-Equity RatioN/A
Current Ratio5.14
Quick Ratio5.14
Price-To-Earnings
Trailing P/E Ratio-5.63
Forward P/E Ratio-6.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$900,000.00
Price / Sales556.63
Cash FlowN/A
Price / CashN/A
Book Value$1.62 per share
Price / Book10.22
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-67,820,000.00
Net Margins-4,689.63%
Return on Equity-101.93%
Return on Assets-82.04%
Miscellaneous
Employees37
Outstanding Shares30,270,000
Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.71) by $0.02. Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 101.93%. View Stemline Therapeutics' Earnings History.
When is Stemline Therapeutics' next earnings date?
What price target have analysts set for STML?
4 brokerages have issued 12 month price targets for Stemline Therapeutics' shares. Their forecasts range from $22.00 to $38.00. On average, they expect Stemline Therapeutics' stock price to reach $30.00 in the next year. View Analyst Ratings for Stemline Therapeutics.
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include Insmed (INSM), Spectrum Pharmaceuticals (SPPI), Prestige Brands (PBH), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Akorn (AKRX), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Zogenix (ZGNX), Myovant Sciences (MYOV) and G1 Therapeutics (GTHX).
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 52)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 58)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 53)
Has Stemline Therapeutics been receiving favorable news coverage?
Media coverage about STML stock has trended somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stemline Therapeutics earned a news impact score of 0.18 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Stemline Therapeutics' major shareholders?
Stemline Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.20%), Lyon Street Capital LLC (4.10%), Citadel Advisors LLC (1.93%), venBio Select Advisor LLC (1.73%), Nexthera Capital LP (1.73%) and Artal Group S.A. (1.32%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.
Which institutional investors are selling Stemline Therapeutics stock?
STML stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S and Trexquant Investment LP. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.
Which institutional investors are buying Stemline Therapeutics stock?
STML stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, venBio Select Advisor LLC, Nexthera Capital LP, Lyon Street Capital LLC, Point72 Asset Management L.P., Artal Group S.A., BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Stemline Therapeutics.
How do I buy shares of Stemline Therapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $16.55.
How big of a company is Stemline Therapeutics?
Stemline Therapeutics has a market capitalization of $517.68 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Stemline Therapeutics employs 37 workers across the globe.
How can I contact Stemline Therapeutics?
Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for Stemline Therapeutics (STML)
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
